Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer | Zendy

Vipin Lohiya | Zendy; Jeanny B. AragonChing | Zendy; Guru Sonpavde | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Vipin Lohiya,

Jeanny B. AragonChing,

Guru Sonpavde

Publication year - 2016

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s34535

Subject(s) - cabazitaxel , enzalutamide , docetaxel , prostate cancer , medicine , chemotherapy , oncology , abiraterone , cancer , androgen receptor , androgen deprivation therapy

Chemotherapy using the taxanes, docetaxel and cabazitaxel, remains an important therapeutic option in metastatic castration-resistant prostate cancer (CRPC). However, despite the survival benefits afforded by these agents, the survival increments are modest and resistance occurs universally. Efforts to overcome resistance to docetaxel by combining with biologic agents have heretofore been unsuccessful. Indeed, resistance to these taxanes is also associated with cross-resistance to the antiandrogen drugs, abiraterone and enzalutamide. Here, we discuss the various mechanisms of resistance to chemotherapy in metastatic CRPC and the potential role of emerging regimens and agents in varying clinical phases of development.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research